ALK-positive NSCLC – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

In a subset of non-small cell lung cancer (NSCLC) patients, a rare occurrence of rearrangements exists within the Anaplastic lymphoma kinase (ALK) gene. These alterations induce perpetual activation of the ALK kinase, subsequently leading to the formation of ALK-driven tumors. Individuals harboring such rearrangements exhibit heightened sensitivity to ALK inhibitors like crizotinib, ceritinib, and alectinib. ALK-positive NSCLC occurs in approximately 1 out of every 25 NSCLC cases. ALK-positive tumor patients typically skew towards a younger demographic and are more commonly found among never-smokers or light smokers. Indeed, ALK rearrangements are observed in 12% of never-smokers, contrasting to the mere 2% incidence in former or current smokers. Notably, ALK rearrangements seldom coincide with activating mutations in EGFR or KRAS. In comparison to those with EGFR-mutant NSCLC, patients with ALK-positive tumors exhibit a higher likelihood of being male. Furthermore, individuals with advanced ALK-positive NSCLC face an augmented risk of developing brain metastases, a significant contributor to both morbidity and mortality. For diagnostic purposes, the Fluorescence in situ hybridization (FISH) assay, particularly the Vysis® ALK Break-Apart FISH Probe Kit test from Abbott Molecular, stands as the recommended method for detection. Various second and third-generation tyrosine kinase inhibitors (TKIs) have been formulated to address resistance to treatment, effectively targeting numerous ALK resistance mutations. Notably, studies have shown that first-line therapy employing alectinib, ceritinib, lorlatinib, or brigatinib surpasses crizotinib or chemotherapy, where applicable, in managing patients with ALK-rearranged disease.

Thelansis’s “ALK-positive NSCLC Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ALK-positive NSCLC treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of ALK-positive NSCLC across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

ALK-positive NSCLC Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: ALK-positive NSCLC – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033